An Observational Study to Assess the Use of Intravitreal Aflibercept Injections in a Routine "Treat and Extend" Regimen in Treatment-naïve Patients Diagnosed With Wet Age-related Macular Degeneration
Phase of Trial: Phase IV
Latest Information Update: 09 Jan 2019
Price : $35 *
At a glance
- Drugs Aflibercept (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms ASTERIA
- Sponsors Bayer
- 02 Jan 2019 Status changed from active, no longer recruiting to completed.
- 21 Nov 2018 Status changed from recruiting to active, no longer recruiting.
- 16 Sep 2018 Planned End Date changed from 1 Nov 2018 to 30 Nov 2018.